Jasper Therapeutics, Inc. (JSPR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2200 Bridge Pkwy
Redwood City, CA 94065
United States of America (the)
Phone
650 549 1400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
January 10, 2020
| Name | Title | Pay | Year Born |
| Jeetinder Singh Mahal | President, COO, CEO & Director | 610,050 | 1972 |
| Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director | 46,300 | 1956 |
| Thomas G. Wiggans | Executive Chairman | 70,000 | 1952 |
| Herbert C. Cross | Chief Financial Officer & Corporate Secretary | 603,925 | 1972 |
| Luca Di Noto | Senior Vice President of Technical Operations | 0 | N/A |
| Alex Gray | Head of Investor Relations | 0 | N/A |
| Matthew Ford | Senior Vice President of Human Resources | 0 | N/A |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.